Publications by authors named "C Broome"
Background: Cold agglutinin disease (CAD) is a rare subtype of autoimmune haemolytic anaemia characterised by classical complement pathway-mediated haemolysis, fatigue, and poor quality of life (QoL). Sutimlimab, a C1s inhibitor, rapidly halted haemolysis, and improved patient-reported outcomes (PROs) in patients with CAD in two phase 3 trials (CARDINAL and CADENZA). Here we report PROs from the CADENZA open-label extension (Part B).
View Article and Find Full Text PDFArticle Synopsis
- Cold agglutinin disease (CAD) is a rare autoimmune condition causing anemia, and sutimlimab, which inhibits a key part of the immune system, showed effectiveness in reducing symptoms like hemolysis and fatigue in the CADENZA Part A study.
- In Part B of the CADENZA study, 32 out of 39 patients continued treatment for about 99 weeks, showing sustained improvements in hemoglobin, bilirubin levels, and quality of life measures, with no severe adverse effects reported.
- Despite the promising results, stopping sutimlimab led to a return of disease symptoms, indicating that while the treatment is effective, continuous management is necessary to maintain its benefits.
Please visit https://bit.ly/AJHpodcast to complete the accredited learning activity and receive CME credit or NCPD contact hours. Because immune-mediated rare blood disorders are uncommon, healthcare providers often lack the knowledge and experience necessary to identify, diagnose, and treat them in accordance with best practices.
View Article and Find Full Text PDF